Abstract: A method for enabling one or more nodes to communicate with an access point (AP) according to a CSMA/CA protocol is provided. In one embodiment of the method, when the individual node enters into a state of having at least one packet of data to be transmitted to the AP, the individual node waits for a non-zero deterministic delay so that any packet arrived during the delay is allowed to be aggregated and transmitted upon one transmission opportunity, thereby improving channel utilization. The delay is determined such that a predicted system throughput is maximized. It is found that the system throughput is significantly affected by the relationship between the delay and the number of the one or more nodes. Hence, the delay is advantageously determined according to the number of the one or more nodes. After the delay expires, the individual node initiates a contending procedure.

Abstract: A method for coding data includes: representing a first data in digital form as digital information; transforming the digital information into a first Gaussian integer; determining a relationship between the first Gaussian integer and a second Gaussian integer; and deriving, based on the determined relationship, a key for converting between the first Gaussian integer and the second Gaussian integer so as to associate the first data with a second data represented by the second Gaussian integer. The present invention also provides a system and a non-transient computer readable medium for implementing the method.

Abstract: This invention provides a method of treating lung cancer including administering a therapeutically effective amount of a compound of 0089-0022 formula I to a subject in need thereof. The compound activates pyruvate kinase M2 isoform (PKM2) to treat the lung cancer. In one example, the lung cancer is Non-Small Cell Lung Cancer (NSCLC).

Abstract: One example embodiment is a method executed by a microcontroller with a Pulse Width Modulation (PWM) circuit to control a semi-dual-active-bridge (SDAB) converter that includes a first side bridge circuit, a second side bridge circuit and a transformer. The microcontroller determines a current operation mode and a target operation mode of the SDAB converter. The microcontroller determines an optimal ratio and calculates changes of each gating signal that are applied to the first side bridge circuit and the second side bridge circuit respectively.

Abstract: In widely deployed wireless “hot-spot” networks, nodes frequently join or leave, inelastic/elastic and saturated/non-satuarted flows coexist. In such dynamic and diverse environments, it is challenging to maximize the channel utilization while providing satisfactory user experiences. In this invention, one proposes a novel contention-on-demand (CoD) MAC scheme to address this problem. The CoD scheme consists of a fixed-CW algorithm, a dynamic-CW algorithm, and an admission control unit. The fixed-CW algorithm allows elastic flows to access limited system bandwidth; the dynamic-CW algorithm enables inelastic flows to contend for channel on demand and quickly adapt to network change; and the admission control unit rejects overloaded traffic for providing good user experiences. One then performs an asymptotic analysis to develop a simple but efficient admission control rule. Finally, extensive simulations verify that the scheme is very effective and the theoretical result is very accurate.

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

Abstract: The present invention relates to an oridonin functionalized selenium nanoparticle, method of preparing and use thereof for anti-cancer and anti-inflammatory treatments. The present invention provides oridonin functionalized selenium nanoparticle that is stable, water soluble and storable.

Abstract: Due to the trend of using larger wafer diameter and smaller lot size, cluster tools need to switch from processing one lot of wafers to another frequently. It leads to more transient periods in wafer fabrication. Their efficient scheduling and control problems become more and more important. It becomes difficult to solve such problems, especially when wafer residency time constraints must be considered. This work develops a Petri net model to describe the behavior during the start-up transient processes of a single-arm cluster tool. Then, based on the model, for the case that the difference of workloads among the steps is not too large and can be properly balanced, a scheduling algorithm to find an optimal feasible schedule for the start-up process is given. For other cases schedulable at the steady state, a linear programming model is developed to find an optimal feasible schedule for the start-up process.

Abstract: A super-resolution method for generating a high-resolution (HR) image from a low-resolution (LR) blurred image is provided. The method is based on a transform-invariant directional total variation (TI-DTV) approach with Schattenp=1/2 (S1/2-norm) and L1/2-norm penalties. The S1/2-norm and the L1/2-norm are used to induce a lower-rank component and a sparse component of the LR blurred image so as to determine an affine transform to be adopted in the TI-DTV approach. In particular, the affine transform is determined such that a weighted sum of the S1/2-norm and the L1/2-norm is substantially minimized. Based on the alternating direction method of multipliers (ADMM), an iterative algorithm is developed to determine the affine transform. The determined affine transform is used to transform a candidate HR image to a transformed image used in computing a directional total variation (DTV), which is involved in determining the HR image.

Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analog, (Z)3,4,5,4?-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analog to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.

Abstract: The present invention discloses that a method of treating cancer, preferably non-small cell lung cancer, comprises administrating mitoxantrone. The present invention also discloses a method of inhibiting ROS1 kinase comprising administrating mitoxantrone. A pharmaceutical composition comprising mitoxantrone is also disclosed.

Abstract: A battery charger with power factor correction is provided. In particular, the battery charger is configured to work in a discontinuous current mode with a power factor that is almost unity but no bulky electrolytic capacitor is needed in the charger. The charger has a rectification circuit producing a rectified voltage to a first controllable switching circuit, whose output is fed to a series resonant tank series-connecting a first winding of a high-frequency transformer. The second winding thereof is connected to a second controllable switching circuit, whose output is a DC voltage for battery charging. The charger includes a control unit for generating a first control signal and a second control signal to control the first and the second controllable switching circuits, respectively, such that the current flowing in the first winding is substantially phase-aligned with the first control signal's waveform, thereby facilitating power factor correction.

Abstract: A method and a device for information system access authentication are disclosed. The method includes: performing anonymous authentication to a random verification code generated according to a login request for accessing an information system of a client, and authenticating acquired user name and password information when the anonymous authentication is successful. The device includes an verification code authentication module and a user name and password authentication module connected to the verification code authentication module, wherein the verification code authentication module is configured to perform anonymous authentication to a random verification code generated according to a login request for accessing an information system of client; and the user name and password authentication module is configured to authenticate acquired user name and password information when the anonymous authentication is successful.

Abstract: The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation.